1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    




































































































































    Dynamic Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin | American Journal of Neuroradiology  
    


















    





























    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      



          


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Research ArticleBRAIN

  
      

  
      
Dynamic Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin
  
    	
Soonmee Cha, Edmond A. Knopp, Glyn Johnson, Andrew Litt, Jon Glass, Michael L. Gruber, Stanley Lu and David Zagzag

  
    	
American Journal of Neuroradiology May 2000,  21 (5) 881-890; 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. ↵
    Chang SM,  Prados MD.   Chemotherapy for gliomas. Curr Opin Oncol 1995;7:207-213
    PubMed
  2. Balmaceda C,  Fetell MR,  Hesdorffer C.   Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study. Cancer Chemother Pharmacol 1997;40:72-74
    CrossRefPubMedWeb of Science
  3. Friedman HS,  Schold SC Jr,  Djang WT,   et al.  Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor. Neurology 1989;39:62-66
    Abstract/FREE Full Text
  4. ↵
    Burger P.   Malignant astrocytic neoplasms: classification, pathology, anatomy, and response to therapy. Semin Oncol 1986;13:16-20
    PubMed
  5. ↵
    D'Amato RJ,  Loughnan MS,  Flynn E,   et al.  Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-4085
    Abstract/FREE Full Text
  6. D'Arcy PF,  Griffin JP.   Thalidomide revisited. Adverse Drug React Toxicol Rev 1994;13:65-76
    PubMedWeb of Science
  7. ↵
    Moreira AL,  Friedlander DR,  Shif B,   et al.  Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 1999;43:109-114
    CrossRefPubMed
  8. ↵
    Fine HA.   Novel biologic therapies for malignant gliomas: antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin 1995;13:827-846
    PubMed
  9. ↵
    Glass J,  Gruber ML,  Nirenberg A.   Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme (abstract). Proc Am Soc Clin Oncol 1999;18:144a
  10. ↵
    Knopp EA,  Cha S,  Johnson G,   et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791-798
    CrossRefPubMedWeb of Science
  11. ↵
    Aronen HJ,  Gazit IE,  Louis DN,   et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51
    PubMedWeb of Science
  12. Ernst TM,  Chang L,  Witt MD,   et al.  Cerebral toxoplasmosis and lymphoma in AIDS: perfusion MR imaging experience in 13 patients. Radiology 1998;208:663-669
    PubMed
  13. ↵
    Press W,  Flannery B,  Teukolsky S,   et al.  Numerical Recipes in C: The Art of Scientific Computing..  Cambridge: Cambridge University Press; 1988 
  14. ↵
    Rosen BR,  Belliveau JW,  Vevea JM,   et al.  Perfusion imaging with NMR contrast agents. Magn Res Med 1990;14:249-265
    PubMedWeb of Science
  15. ↵
    Macdonald D,  Cascino T,  Schold SJ,   et al.  Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280
    Abstract
  16. Burger PC,  Vogel FS,  Green SB,   et al.  Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985;56:1106-1111
    CrossRefPubMedWeb of Science
  17. Brem S.   The role of vascular proliferation in the growth of brain tumors. Clin Neurosurg 1976;23:440-453
    PubMed
  18. ↵
    Scherer HJ.   The forms of growth in gliomas and their practical significance. Brain 1940;63:1-35
    FREE Full Text
  19. ↵
    Hoshino T.   Cell kinetics of glial tumors. Rev Neurol 1992;148:396-401
    PubMed
  20. Nagashima T,  Hoshino T.   A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method. No Shinkei Geka 1984;12:1007-1018
    PubMed
  21. ↵
    Maxwell M,  Naber SP,  Wolfe HJ,   et al.  Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res 1991;51:1345-1351
    Abstract/FREE Full Text
  22. ↵
    Kleihues P,  Soylemezoglu F,  Schauble B,   et al.  Histopathology, classification, and grading of gliomas. Glia 1995;15:211-221
    CrossRefPubMedWeb of Science
  23. ↵
    Obwegeser A,  Ortler M,  Seiwald M,   et al.  Therapy of glioblastoma multiforme: a cumulative experience of 10 years. Acta Neurochir 1995;137:29-33
    CrossRefPubMed
  24. ↵
    Gruber ML,  Glass J,  Choudhri H,   et al.  Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. Am J Clin Oncol 1998;21:338-340
    CrossRefPubMedWeb of Science
  25. Jeremic B,  Grujicic D,  Jevremovic S,   et al.  Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992;10:1074-1077
    Abstract
  26. Kruse CA,  Cepeda L,  Owens B,   et al.  Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997;45:77-87
    CrossRefPubMedWeb of Science
  27. Hayes RL,  Koslow M,  Hiesiger EM,   et al.  Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995;76:840-852
    CrossRefPubMed
  28. Cloughesy TF,  Gobin YP,  Black KL,   et al.  Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol 1997;35:121-131
    CrossRefPubMed
  29. Poisson M,  Pereon Y,  Chiras J,   et al.  Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 1991;10:139-144
    CrossRefPubMed
  30. Twelves CJ,  Ash CM,  Miles DW,   et al.  Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 1991;27:481-483
    PubMed
  31. ↵
    Lenz W.   A short history of thalidomide embryopathy. Teratology 1988;38:203-215
    CrossRefPubMedWeb of Science
  32. ↵
    Sheskin J.   Further observation with thalidomide in lepra reactions. Lepr Rev 1965;36:183-187
    PubMed
  33. ↵
    Schroder JM,  Sellhaus B,  Wohrmann T,   et al.  Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early wallerian degeneration. Acta Neuropathol 1995;89:415-419
    PubMed
  34. Corral LG,  Muller GW,  Moreira AL,   et al.  Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2:506-515
    PubMedWeb of Science
  35. Klausner JD,  Makonkawkeyoon S,  Akarasewi P,   et al.  The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-257
    CrossRefPubMedWeb of Science
  36. Mellin G,  Katzenstein M.   The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital abnormalities. N Engl J Med 1962;23:1184-1190
  37. Minchinton AI,  Fryer KH,  Wendt KR,   et al.  The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339-343
    PubMed
  38. Zwingenberger K,  Wnendt S.   Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflamm 1996;46:177-211
  39. McBride W.   Thalidomide and congenital abnormalities (Letter).  Lancet 1961;1358 
  40. ↵
    Sheskin J.   The treatment of lepra reaction in lepromatous leprosy: fifteen years' experience with thalidomide. Int J Dermatol 1980;19:318-322
    CrossRefPubMedWeb of Science
  41. ↵
    O'Reilly MS,  Holmgren L,  Chen C,   et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692
    CrossRefPubMedWeb of Science
  42. Wu Z,  O'Reilly MS,  Folkman J,   et al.  Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 1997;236:651-654
    CrossRefPubMedWeb of Science
  43. ↵
    Forsting M,  Albert FK,  Kunze S,   et al.  Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. AJNR Am J Neuroradiol 1993;14:77-87
    Abstract/FREE Full Text
  44. ↵
    Felix R,  Schorner W,  Laniado M,   et al.  Brain tumors: MR imaging with gadolinium-DTPA. Radiology 1985;156:681-688
    PubMedWeb of Science
  45. Bird CR,  Drayer BP,  Medina M,   et al.  Gd-DTPA-enhanced MR imaging in pediatric patients after brain tumor resection. Radiology 1988;169:123-126
    PubMedWeb of Science
  46. ↵
    Sage MR.   Blood-brain barrier: phenomenon of increasing importance to the imaging clinician. AJR Am J Roentgenol 1982;138:887-898
    PubMedWeb of Science
  47. ↵
    Alvord EJ,  Shaw C-M,  Richards T.   The relative rates of cellular proliferation and infiltration and the histologic definition of gliomas. Can J Neurol Sci 1993;20:83
  48. ↵
    Tracqui P,  Cruywagen GC,  Woodward DE,   et al.  A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth. Cell Prolif 1995;28:17-31
    CrossRefPubMedWeb of Science
  49. ↵
    Smith M,  Thompson J,  Castillo M,   et al.  MR of recurrent high-grade astrocytomas after intralesional immunotherapy. AJNR Am J Neuroradiol 1996;17:1065-1071
    Abstract
  50. ↵
    Castillo M,  Kwock L,  Mukherji SK.   Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17:1-15
    PubMedWeb of Science
  51. Castillo M,  Kwock L,  Scatliff J,   et al.  Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am 1998;6:1-20
    PubMed
  52. Taylor JS,  Langston JW,  Reddick WE,   et al.  Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996;36:1251-1261
    CrossRefPubMed
  53. Wald LL,  Nelson SJ,  Day MR,   et al.  Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997;87:525-534
    PubMedWeb of Science
  54. Sugahara T,  Korogi Y,  Kochi M,   et al.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60
    CrossRefPubMedWeb of Science
  55. Krabbe K,  Gideon P,  Wagn P,   et al.  MR diffusion imaging of human intracranial tumours. Neuroradiology 1997;39:483-489
    CrossRefPubMed
  56. Edelman RR,  Mattle HP,  Atkinson DJ,   et al.  Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology 1990;176:211-220
    PubMed
  57. ↵
    Ostergaard L,  Sorensen AG,  Kwong KK,   et al.  High resolution measurement of cerebral blood flow using intravascular tracer bolus passages, II: experimental comparison and preliminary results. Magn Reson Med 1996;36:726-736
    CrossRefPubMedWeb of Science
  58. ↵
    Detre JA,  Leigh JS,  Williams DS,   et al.  Perfusion imaging. Magn Reson Med 1992;23:37-45
    CrossRefPubMedWeb of Science
  59. Edelman RR,  Siewert B,  Darby DG,   et al.  Qualitative mapping of cerebral blood flow and functional localization with echo-planar MR imaging and signal targeting with alternating radio frequency. Radiology 1994;192:513-520
    PubMedWeb of Science
  60. Kim SG.   Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique: application to functional mapping. Magn Reson Med 1995;34:293-301
    CrossRefPubMedWeb of Science
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Dynamic Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin
  
    	
Soonmee Cha, Edmond A. Knopp, Glyn Johnson, Andrew Litt, Jon Glass, Michael L. Gruber, Stanley Lu, David Zagzag

  
    	
American Journal of Neuroradiology May 2000, 21 (5) 881-890; 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement